Iranian Journal of Virology مجله ویروس شناسی ایران

Purpose: This study was completed to assess the immunogenicity and safety of the FAKHRAVAC and BBIBP-CorV vaccines as a booster dose in the population with a history of receiving two doses of BBIBP-CorV vaccine. Methods: In this double-blind, parallel clinical trial, we randomly assigned healthy adults with a history of receiving two doses of the BBIBP-CorV vaccine, who then received either the FAKHRAVAC or BBIBP-CorV vaccine as a booster dose. The trial is registered in the Iranian Registry of Clinical Trial document depository (Code: IRCT20210206050259N4). Results: The outcomes that were monitored in this study were serum neutralizing antibody (Nab) activity, immunoglobulin G (IgG) level, local and systemic adverse reactions, serious adverse events, suspected unexpected serious adverse reactions, and medically attended adverse events. After administering vaccines to 435 participants, the most frequent local and systemic adverse reactions were tenderness and nausea in 23.7% and 1.4% of cases, respectively. All adverse events were mild, occurred at a similar incidence in the two groups, and were resolved within a few days. Conclusions: On the 14th day after the booster dose injection, the seroconversion rate (i.e., four-fold increase) of Nabs for seronegative participants were 87% and 84.6% in the FAKHRAVAC^® and BBIBP-CorV groups, respectively. This study shows that the FAKHRAVAC^® vaccine, as a booster dose, has a similar function to the BBIBP-CorV vaccine in terms of increasing the titer of virus-neutralizing antibodies, the amount of specific antibodies, and safety.

Diabetic patients face an elevated cardiovascular disease burden, often requiring coronary artery bypass grafting (CABG). However, evidence regarding post-CABG outcomes in diabetic versus non-diabetic patients is inconsistent, and data from the Iranian population are particularly scarce. This study was conducted to clarify this ambiguity by comparing short-term post-CABG complications between these groups. A retrospective cohort study analyzed data from the Yazd Cardiovascular Disease Registry (YCDR) for all CABG patients (2017–2018) at Afshar Hospital. Patients were stratified into diabetic (n=592) and non-diabetic (n=694) groups. We collected standardized data on demographics, comorbidities (including diabetes), and in-hospital major postoperative complications following CABG, such as reoperation, mortality, infections, renal complications, neurological complications (including TIA, stroke, and seizure), and pulmonary complications. The frequency distribution of female sex (36.66% vs. 21.90%), hypertension (65.03% vs. 44.52%), and hyperlipidemia (39.02% vs. 23.20%) in diabetic patients was significantly higher than in non-diabetic patients (p0.05). However, seizure occurred exclusively in the diabetic group (1.1% vs. 0%; p=0.049). Logistic regression analysis demonstrated that diabetes mellitus was not an independent predictor of overall postoperative complications. In this cohort, diabetes was not an independent risk factor for most short-term post-CABG complications. The exception was a higher seizure incidence in diabetic patients, warranting further mechanistic investigation. Larger prospective studies are needed to confirm these findings.